ATE440888T1 - Verfahren zur herstellung von glatiramer - Google Patents

Verfahren zur herstellung von glatiramer

Info

Publication number: ATE440888T1
Authority: AT; Austria
Prior art keywords: glatiramer; producing; producing glatiramer
Prior art date: 2004-10-29

Application number

AT05824006T

Other languages

English (en)

Inventor

Anup Ray

Hiren Patel

Johannes Ludescher

Mariappan Anbazhagan

Mahendra Patel

Ingolf Macher

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-29

Filing date

2005-10-27

Publication date

2009-09-15

2005-10-27 Application filed by Sandoz Ag filed Critical Sandoz Ag

2009-09-15 Application granted granted Critical

2009-09-15 Publication of ATE440888T1 publication Critical patent/ATE440888T1/de

Links

YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 title 1
108010072051 Glatiramer Acetate Proteins 0.000 title 1
229940042385 glatiramer Drugs 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Polymers & Plastics (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Polyamides (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT05824006T 2004-10-29 2005-10-27 Verfahren zur herstellung von glatiramer ATE440888T1 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US62334604P	2004-10-29	2004-10-29
US65153505P	2005-02-09	2005-02-09
US65137205P	2005-02-09	2005-02-09
US72390105P	2005-10-05	2005-10-05
PCT/US2005/039003 WO2006050122A1 (en)	2004-10-29	2005-10-27	Processes for preparing glatiramer

Publications (1)

Publication Number	Publication Date
ATE440888T1 true ATE440888T1 (de)	2009-09-15

Family

ID=36046637

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05824006T ATE440888T1 (de)	2004-10-29	2005-10-27	Verfahren zur herstellung von glatiramer

Country Status (14)

Country	Link
US (5)	US20060154862A1 (de)
EP (1)	EP1807467B1 (de)
JP (1)	JP5297653B2 (de)
CN (1)	CN101044188B (de)
AR (1)	AR052321A1 (de)
AT (1)	ATE440888T1 (de)
AU (1)	AU2005302500B2 (de)
CA (1)	CA2583589C (de)
DE (1)	DE602005016292D1 (de)
ES (1)	ES2331015T3 (de)
IL (2)	IL182581A (de)
SI (1)	SI1807467T1 (de)
TW (1)	TWI307349B (de)
WO (1)	WO2006050122A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7429374B2 (en)	2001-12-04	2008-09-30	Teva Pharmaceutical Industries, Ltd.	Process for the measurement of the potency of glatiramer acetate
HRP20160455T1 (hr)	2004-09-09	2016-07-15	Yeda Research And Development Co., Ltd.	Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
AR052321A1 (es) *	2004-10-29	2007-03-14	Sandoz Ag	Procesos para la preparacion de un polipeptido
WO2007081975A2 (en) *	2006-01-11	2007-07-19	Teva Pharmaceutical Industries, Ltd.	Method of treating multiple sclerosis
JP2009542864A (ja) *	2006-07-05	2009-12-03	モメンタファーマシューティカルズインコーポレイテッド	コポリマー１の調製のための改良法
US8753833B2 (en)	2007-06-21	2014-06-17	Momenta Pharmaceuticals, Inc.	Copolymer assay
WO2009017775A2 (en) *	2007-08-02	2009-02-05	Scinopharm Taiwan Ltd.	Process for the preparation of a polypeptide
ES2449865T5 (es)	2008-04-16	2022-11-18	Momenta Pharmaceuticals Inc	Análisis de composiciones de copolímeros de aminoácidos
US8399600B2 (en)	2008-08-07	2013-03-19	Sigma-Aldrich Co. Llc	Preparation of low molecular weight polylysine and polyornithine in high yield
KR20110059606A (ko) *	2008-08-07	2011-06-02	시노팜 타이완 리미티드	글라티라머 아세테이트의 합성
AR074881A1 (es)	2008-12-24	2011-02-16	Synthon Bv	Un proceso para purificar una mezcla de polimeros
RU2011144566A (ru)	2009-04-03	2013-05-10	Момента Фармасьютикалз, Инк.	Контроль сополимерных композиций
CA2697570C (en) *	2009-07-15	2011-11-01	Teva Pharmaceutical Industries, Ltd.	Reduced volume formulation of glatiramer acetate and methods of administration
US8920373B2 (en)	2009-07-15	2014-12-30	Teva Pharmaceutical Industries, Ltd.	Reduced volume formulation of glatiramer acetate and methods of administration
NZ598661A (en)	2009-08-20	2013-02-22	Yeda Res & Dev	Low frequency glatiramer acetate therapy
EP2526420A4 (de) *	2009-11-17	2013-09-18	Ares Trading Sa	Verfahren zur verbesserung der gestalt, bioverfügbarkeit und effizienz von zufälligen sequenzpolymerzusammensetzungen mit serumproteinbasiertem nachweis von zufälligen sequenzpolymerzusammensetzungen
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en)	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
JP2013529194A (ja) *	2010-04-27	2013-07-18	ドクターレディズラボラトリーズリミテッド	ポリペプチドおよびその塩の調製
US9109006B2 (en) *	2010-07-29	2015-08-18	Santhanakrishnan Srinivasan	Glatiramer acetate molecular weight markers
CA2814500A1 (en)	2010-10-11	2012-04-19	Teva Pharmaceutical Industries Ltd	Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
CA2827275A1 (en)	2011-02-14	2012-09-20	Usv Limited	Copolymer-1, process for preparation and analytical methods thereof
WO2012114167A1 (en) *	2011-02-24	2012-08-30	Biocon Limited	Processes for the preparation of glatiramer acetate
WO2013009864A1 (en)	2011-07-11	2013-01-17	Momenta Pharmaceuticals, Inc.	Structure assessment of heterogeneous polypeptide mixtures
WO2013009885A2 (en)	2011-07-11	2013-01-17	Momenta Pharmaceuticals, Inc.	Evaluation of copolymer diethylamide
US8575198B1 (en)	2011-09-07	2013-11-05	Momenta Pharmaceuticals, Inc.	In-process control for the manufacture of glatiramer acetate
HK1200274A1 (en)	2011-10-10	2015-08-07	Teva Pharmaceutical Industries Ltd.	Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
AU2012330728A1 (en) *	2011-11-03	2014-06-26	Biocon Limited	Process for the preparation of random polypeptides and employing circular dichroism as a guidance tool for the manufacture of glatiramer acetate
US20140045740A1 (en) *	2012-08-13	2014-02-13	Momenta Pharmaceuticals, Inc.	Analysis of glatiramer acetate
US9155775B1 (en)	2015-01-28	2015-10-13	Teva Pharmaceutical Industries, Ltd.	Process for manufacturing glatiramer acetate product
WO2017165664A1 (en)	2016-03-23	2017-09-28	A.L.M Holding Company	Batch asphalt mix plant
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh)	2016-08-31	2019-07-05	Mapi医药公司	包含醋酸格拉替雷的储库系统
CN110382052A (zh)	2017-03-26	2019-10-25	Mapi医药公司	用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
CN107082796B (zh) *	2017-05-02	2020-06-09	江苏大学	一种提纯蛋白酶解物中小分子多肽的方法
GB2579600B (en)	2018-12-05	2023-07-05	Byotrol Plc	Anti-viral composition
MX2022000043A (es)	2019-07-01	2022-04-20	Alm Holding Co	Sistema de calentamiento por microondas con tunel de supresion y caracteristicas relacionadas.
US12604376B2 (en)	2021-09-08	2026-04-14	A.L.M. Holding Company	Microwave heating applied to mining and related features

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2657972A (en) *	1952-09-06	1953-11-03	Robert B Woodward	Copolymer of l-leucine and dl-phenylalanine
US3704282A (en) *	1971-04-09	1972-11-28	Sidney Spector	Catecholamine antigens and antibodies specific therefor
IL36670A (en) *	1971-04-21	1974-09-10	Sela M	Therapeutic basic copolymers of amino acids
HU174500B (hu) *	1976-05-05	1980-01-28	Richter Gedeon Vegyeszet	Sposob poluchenija slozhnogo oktapeptidamid-sul'fatnogo ehfira kholecistokhinin-pankreozimina
JPS6053535A (ja) *	1983-09-02	1985-03-27	Nitto Boseki Co Ltd	規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru)	1984-04-28	1985-09-30	Таджикский государственный университет им.В.И.Ленина	Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
DE3684333D1 (de)	1985-06-18	1992-04-16	Univ Emory	Biologisch wirksame kopolymere.
DD257174A3 (de)	1985-12-20	1988-06-08	Ve Forschungszentrum Biotechno	Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
CA2009996A1 (en)	1989-02-17	1990-08-17	Kathleen S. Cook	Process for making genes encoding random polymers of amino acids
DE3930733A1 (de)	1989-09-14	1991-03-28	Roehm Gmbh	Verfahren zur herstellung eines komplexierten arzneimittels
IL113812A (en) *	1994-05-24	2000-06-29	Yeda Res & Dev	Copolymer-1 pharmaceutical compositions containing it and its use
GB9411292D0 (en)	1994-06-06	1994-07-27	Teva Pharma	Pharmaceuticals compositions
CN1173954C (zh) *	1996-01-16	2004-11-03	鲁米根公司	与磷酸酶反应产生化学发光的化合物、组合物和方法
US6271198B1 (en) *	1996-11-06	2001-08-07	Genentech, Inc.	Constrained helical peptides and methods of making same
US6214791B1 (en) *	1997-01-10	2001-04-10	Yeda Research And Development Co. Ltd.	Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6514935B1 (en) *	1997-03-14	2003-02-04	President And Fellows Of Harvard	Methods of treating hypertension
US6632541B2 (en) *	1998-02-10	2003-10-14	Sumitomo Chemical Company, Limited	Olefin-based copolymer composition
US7906153B2 (en) *	1998-04-08	2011-03-15	Theta Biomedical Consulting & Development Co., Inc.	Anti-inflammatory compositions for treating multiple sclerosis
WO2000012517A1 (en) *	1998-08-27	2000-03-09	Teva Pharmaceutical Industries Ltd.	Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US6514938B1 (en)	1998-09-25	2003-02-04	Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6800287B2 (en) *	1998-09-25	2004-10-05	Yeda Research And Development Co., Ltd.	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
AU775073C (en)	1998-11-12	2007-05-03	Yeda Research And Development Co. Ltd.	Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
JP2000256395A (ja) *	1999-01-07	2000-09-19	Takeda Chem Ind Ltd	ポリオール類、その製造法および用途
US6872739B1 (en) *	1999-06-04	2005-03-29	Vereniging Voor Christelijk Wetenshappelikjk Onderwijs	Use of riluzole for the treatment of multiple sclerosis
US6531130B1 (en) *	1999-07-06	2003-03-11	The Board Of Trustees Of The Leland Stanford University	Treatment of demyelinating autoimmune disease with ordered peptides
US6963008B2 (en) *	1999-07-19	2005-11-08	Teva Pharmaceutical Industries Ltd.	Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US6995237B1 (en) *	1999-10-27	2006-02-07	Cel-Sci Corporation	Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions
JP4328050B2 (ja) *	2000-01-20	2009-09-09	イエダリサーチアンドデベロップメントカンパニーリミテッド	神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
US20020077278A1 (en) *	2000-06-05	2002-06-20	Yong V. Wee	Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
IL157073A0 (en) *	2001-01-24	2004-02-08	Harvard College	Therapeutic peptides for demyelinating conditions
US6936599B2 (en) *	2001-04-25	2005-08-30	The Regents Of The University Of California	Estriol therapy for multiple sclerosis and other autoimmune diseases
PE20030701A1 (es) *	2001-12-20	2003-08-21	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
CA2411786C (en) *	2002-11-13	2009-01-27	Brantford Chemicals Inc.	A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
WO2004043995A2 (en) *	2002-11-13	2004-05-27	Apotex Pharmachem Inc.	Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
US6936539B2 (en) *	2003-09-24	2005-08-30	Micron Technology, Inc.	Antireflective coating for use during the manufacture of a semiconductor device
ZA200702591B (en) *	2004-09-09	2009-03-25	Teva Pharma	Process for preparation of mixtures of polypeptides using purified hydrobromic acid
AR052321A1 (es) *	2004-10-29	2007-03-14	Sandoz Ag	Procesos para la preparacion de un polipeptido
US8420605B2 (en) *	2005-09-07	2013-04-16	The University Of Strathclyde	Hydrogel compositions

2005
- 2005-10-27 AR ARP050104513A patent/AR052321A1/es not_active Application Discontinuation
- 2005-10-27 CA CA2583589A patent/CA2583589C/en not_active Expired - Fee Related
- 2005-10-27 JP JP2007539184A patent/JP5297653B2/ja not_active Expired - Fee Related
- 2005-10-27 DE DE602005016292T patent/DE602005016292D1/de not_active Expired - Lifetime
- 2005-10-27 CN CN2005800357997A patent/CN101044188B/zh not_active Expired - Fee Related
- 2005-10-27 WO PCT/US2005/039003 patent/WO2006050122A1/en not_active Ceased
- 2005-10-27 AT AT05824006T patent/ATE440888T1/de active
- 2005-10-27 EP EP05824006A patent/EP1807467B1/de not_active Expired - Lifetime
- 2005-10-27 ES ES05824006T patent/ES2331015T3/es not_active Expired - Lifetime
- 2005-10-27 AU AU2005302500A patent/AU2005302500B2/en not_active Ceased
- 2005-10-27 SI SI200530809T patent/SI1807467T1/sl unknown
- 2005-10-28 TW TW094137997A patent/TWI307349B/zh not_active IP Right Cessation
- 2005-10-28 US US11/262,122 patent/US20060154862A1/en not_active Abandoned
2007
- 2007-04-16 IL IL182581A patent/IL182581A/en not_active IP Right Cessation
- 2007-09-27 US US11/904,422 patent/US8536305B2/en not_active Expired - Fee Related
2010
- 2010-03-18 US US12/726,571 patent/US8729229B2/en not_active Expired - Fee Related
- 2010-03-19 US US12/727,653 patent/US20100234566A1/en not_active Abandoned
- 2010-03-19 US US12/727,758 patent/US20100174048A1/en not_active Abandoned
2014
- 2014-07-10 IL IL233618A patent/IL233618A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
US20100234566A1 (en)	2010-09-16
US20080021200A1 (en)	2008-01-24
DE602005016292D1 (de)	2009-10-08
JP2008518930A (ja)	2008-06-05
TW200634051A (en)	2006-10-01
CN101044188A (zh)	2007-09-26
EP1807467A1 (de)	2007-07-18
IL233618A0 (en)	2014-08-31
WO2006050122A1 (en)	2006-05-11
AU2005302500A1 (en)	2006-05-11
SI1807467T1 (sl)	2009-12-31
US20100234272A1 (en)	2010-09-16
AU2005302500B2 (en)	2008-11-27
CA2583589A1 (en)	2006-05-11
US20100174048A1 (en)	2010-07-08
US20060154862A1 (en)	2006-07-13
TWI307349B (en)	2009-03-11
AR052321A1 (es)	2007-03-14
IL182581A0 (en)	2007-07-24
US8536305B2 (en)	2013-09-17
US8729229B2 (en)	2014-05-20
IL182581A (en)	2015-09-24
EP1807467B1 (de)	2009-08-26
IL233618A (en)	2016-05-31
JP5297653B2 (ja)	2013-09-25
ES2331015T3 (es)	2009-12-18
CN101044188B (zh)	2010-08-04
CA2583589C (en)	2012-04-24

Legal Events

Date

Code

Title

Description

2010-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1807467

Country of ref document: EP

Publication	Publication Date	Title
ATE440888T1 (de)	2009-09-15	Verfahren zur herstellung von glatiramer
ATE408609T1 (de)	2008-10-15	Verfahren zur herstellung von n-phenylpyrazol-1- carboxamiden
DE602005019848D1 (de)	2010-04-22	Verfahren zur herstellung von tad- getrocknetem ti
ATE408604T1 (de)	2008-10-15	Verfahren zur herstellung von 1-alkyl-3- phenyluracilen
ATE399761T1 (de)	2008-07-15	Verfahren zur herstellung von dinitrilen
ATE516816T1 (de)	2011-08-15	Verfahren zur herstellung von impfstoffen
ATE479409T1 (de)	2010-09-15	Verfahren zur herstellung von saugkernen
ATE455105T1 (de)	2010-01-15	Verfahren zur herstellung von difluormethylpyrazolylcarboxylaten
ATE476411T1 (de)	2010-08-15	Verfahren zur herstellung von 3-pentennitril
DE602006015090D1 (de)	2010-08-05	Verfahren zur herstellung von gezielt durchlässigen laminaten
ATE480531T1 (de)	2010-09-15	Verfahren zur herstellung von benzopyran-2- olderivaten
ATE489015T1 (de)	2010-12-15	Verfahren zur herstellung von verschlüssen
ATE457969T1 (de)	2010-03-15	Verfahren zur herstellung von aloe-emodin
ATE308524T1 (de)	2005-11-15	Verfahren zur herstellung von aripiprazole
ATE399157T1 (de)	2008-07-15	Verfahren zur herstellung von telmisartan
DE602004022134D1 (de)	2009-09-03	Verfahren zur herstellung von dinitrilen
ATE553103T1 (de)	2012-04-15	Verfahren zur herstellung von (s)-pantoprazol
DE502005001997D1 (de)	2007-12-27	Verfahren zur herstellung von silanisierten kohlenstoff-nanoröhren
ATE453619T1 (de)	2010-01-15	Verfahren zur herstellung von hydroperoxiden
DE502004004318D1 (de)	2007-08-23	Verfahren zur herstellung von metall-matrix-verbundwerkstoffen
DE50303611D1 (de)	2006-07-06	Verfahren zur herstellung von polyisobuten
ATE444303T1 (de)	2009-10-15	Verfahren zur herstellung von ferrisuccinylcasein
ATE406372T1 (de)	2008-09-15	Verfahren zur herstellung von 3-o-geschützten morphinonen und 3-o-geschützten morphinondienolcarboxylaten
ATE466843T1 (de)	2010-05-15	Verfahren zur herstellung von n-piperidino-1,5- diphenylpyrazol-3-carboxamid-derivaten
ATE549314T1 (de)	2012-03-15	Verfahren zur herstellung von 4-aminochinazolinen